Circulate Health Raises Significant Funding to Fuel Longevity and Therapeutic Expansion
Circulate, officially known as Circulate Health, the Seattle‑area longevity startup focused on therapeutic plasma exchange (TPE) treatments aimed at improving healthspan and reducing biological age, has secured major funding to accelerate its growth and clinical adoption. The company, which has been operating in stealth since its founding and officially launched commercially in January 2024, announced a $12 million seed funding round led by prominent venture capital investors.
The seed round, designed to support both research and the expansion of Circulate’s network of treatment centers, was led by Khosla Ventures, a Silicon Valley firm with a track record of backing innovative health‑tech and longevity companies. Alongside Khosla Ventures, Seaside Ventures, and CSC Ventures participated in the financing, providing additional capital to help scale the company’s therapeutic offerings.
Circulate’s core technology revolves around therapeutic plasma exchange, a procedure that removes a patient’s blood plasma and replaces it with protein solutions, with the aim of clearing inflammatory markers and other biomolecules associated with aging. While TPE has established clinical uses in autoimmune and inflammatory conditions, Circulate is pioneering its use in a preventive and longevity context, partnering with clinics to deliver these treatments to paying customers.
In addition to the initial seed funding, Circulate Health later secured a strategic seed investment from Scrum Ventures, a global venture capital firm known for investing across health, mobility, and technology sectors. This additional capital was aimed at further accelerating research and expanding the company’s clinical footprint, reinforcing investor confidence in Circulate’s approach to TPE therapies and broader health innovations.
The strategic investment from Scrum Ventures underscores growing interest among early‑stage health and longevity investors in companies that bridge cutting‑edge medical concepts with commercial scalability. Circulate’s executive team has highlighted that this funding will be used not only to broaden access to plasma exchange treatments but also to deepen research efforts, including ongoing work to evaluate potential impacts on biomarkers of aging and systemic health.
Circulate’s management believes that strategic capital partners can help the company elevate its research and clinical operations at a time when interest in longevity medicine and preventive interventions is rising. The company’s partnerships with academic and clinical research partners, including longevity researchers and institutes, provide a scientific foundation for its technology while guiding its development priorities.
From a business standpoint, the funding positions Circulate to scale its operations across multiple states in the U.S. and eventually to international markets. With more than two dozen partner clinics already offering its TPE treatments, management has set an ambitious goal to expand that network significantly by year’s end, seeking to establish Circulate as a recognizable brand in preventive and longevity care.
The company’s narrative reflects a broader trend in the health‑tech investment landscape: investors are increasingly debating the value and potential impact of therapies outside traditional pharmaceutical development pipelines. Circulate’s model, which combines existing medical procedures with novel applications for healthspan optimization, represents an example of this shift.
Circulate’s $12 million funding round and follow‑on strategic investment demonstrate that venture capital remains willing to back ventures focused on extending human healthspan, even when scientific and regulatory challenges lie ahead. Backers such as Khosla Ventures, Seaside Ventures, CSC Ventures, and Scrum Ventures bring not only capital but also strategic guidance that the company expects will be instrumental as it navigates research, clinical partnerships, and scaling operations.
As Circulate advances its mission to redefine how therapeutic plasma exchange is deployed in preventive and longevity medicine, the company’s funding success marks a notable milestone in the convergence of biotechnology, preventive health, and venture capital. The coming years will likely determine whether Circulate’s model can translate early clinical insights into broader health outcomes and commercial success.
